Across TCGA pan-cancer cohorts, PAX5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PAX5 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PAX5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PAX5 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

THYM, DLBC, and UCEC are the cancer types where PAX5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
DLBC	OS	Median	All	0.053	0.936	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	OS	Median	All	1.000	0.547	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PAX5 tumor-vs-normal RNA expression · all PAX5 data types